Description
ELISA Kit for the detection of Squamous Cell Carcinoma Antigen (SCCA) variants Immune Complexes (SCCA-IgM) in Hepatocellular Carcinoma (HCC)
HCC Early Detection
Surveillance of Cirrhotic Patients
Monitoring of Treatment
An ELISA assay for Hepatocellular Carcinoma (HCC) detection in patient sera. Published studies have shown that Hepa-IC has a 70% sensitivity rate and a 100% specificity over healthy controls. These figures are much higher than the gold standard serological marker for HCC, Alpha fetoprotein (AFP). Hepa-IC can be used to evaluate the progress of HCC development in cirrhotic patients and can be used to monitor chronic hepatitis patients, thus increasing the application of Hepa-IC to an even larger patient population. In addition, Hepa-IC has demonstrated the ability to evaluate chronic hepatitis patients’ response to interferon and lavimudine therapies.
Usage
- Diagnosis of HCC
- Assessment of HCC risk
- Prognosis of HCC patients
- Monitoring of HCC therapeutic treatment
- Assessment of the evaluation of liver diseases in HCV infected patients
- Prediction of therapeutic outcome in HCV treatments
- Screening HCV Cirrhosis patients
Hepa-IC allows the diagnosis of HCC in the early stages of development, the possibility to monitor at risk populations such as chronic hepatitis and cirrhotic patients and the ability to evaluate patients response to therapies.
Hepatocellular Carcinoma (HCC) is one of the
most frequent and lethal cancer forms worldwide, ranking four for incidence rate. Its
prognosis is very poor, with less than 5% survival rate after five years from diagnosis.
|
BIOMARKER |
SENSITIVITY |
SPECIFICITY |
PPV |
PNV |
| SCCA-IgM 120 AU/mL | ||||
| HCC vs Control | 70% | 100% | 100% | 77% |
| HCC vs | 70% | 74% | 73% | 71% |
| HCC vs CH | 70% | 82% | 80% | 73% |
| AFP 20 ng/mL | ||||
| HCC vs Control | 42% | 100% | 100% | 63% |
| HCC vs CR | 42% | 84% | 72% | 59% |
| HCC vs CH | 42% | 98% | 95% | 63% |
Early detection of HCC is still difficult due to the lack of adequate biomarkers to clearly
differentiate HCC from benign liver lesion with
high sensitivity and high specificity. The most
widely used serologic marker to detect HCC is
Alpha-Fetoprotein (AFP), which is elevated in a wide number of HCC patients (30-60%) but
with low specificity (70-80%).
A new biomarker for HCC, Squamous Cell
Carcinoma Antigen (SCCA) variants, has been
recently identified in all surgically resected HCC but in none of the control normal livers, as PPVpositive predictive value PNV negative predictive value
detected by immunohistochemistry
with anti-SCCA variants antibody (Hepa-Ab, Xeptagen)
